Neon Nettle
© 2019 Neon Nettle

Subscribe to our mailing list

Advertise Contact About Us Our Writers T&C's Privacy Support Us © 2019 Neon Nettle All Rights Reserved.

FDA Officially Lists Psychedelic Drugs As ‘Breakthrough' Depression Therapy

Food and Drug Administration admit magic mushrooms help depression

 on 26th October 2018 @ 4.00pm
food and drug administration admit magic mushrooms help depression © press
Food and Drug Administration admit magic mushrooms help depression

Psychedelic drug researchers are finally able to begin providing psychiatric patients with psilocybin, the main ingredient in n magic mushrooms, following the official recognition by the US Food and Drug Administration (FDA).

Psilocybin therapy for treatment-resistant depression, covering around 50 percent of patients diagnosed with clinical depression in the US, has been given a “Breakthrough Therapy Designation” by the FDA.

The historic decision essentially admits that elements within psychedelics like magic mushrooms, significantly help people with depression.

“The Breakthrough Therapy designation is a strong endorsement for the potential of psilocybin therapy,” Robin Carhart-Harris, head of the Psychedelic Research Group at Imperial College London said.

fda officially lists psychedelic drugs as    breakthrough  depression therapy © press

According to RT: The Breakthrough Therapy designation was created in 2012 to expedite approvals for drugs that display a clear advantage over currently available alternatives used to treat severe or life-threatening conditions.

While it does not necessarily assure that a drug will make it to market, it does indicate that the administration believes further research would be beneficial.

“This is great news for patients. We are excited to be taking this work forward with our clinical trial on psilocybin therapy for treatment-resistant depression,” said George Goldsmith, the executive chairman of Compass, in a statement.

Researchers have advised a rescheduling down to Schedule IV, the category that includes drugs like Xanax and Ambien.

For context, opioids used as prescription painkillers are currently considered Schedule II drugs; medically helpful, but with the high potential for abuse.

fda officially lists psychedelic drugs as    breakthrough  depression therapy © press

The FDA has not offered any official comment on the decision as of yet, citing the confidential status of Breakthrough Therapy applications.

Psilocybin is currently undergoing clinical trials and if it passes those the FDA will be forced to change the drug’s restrictive Schedule 1 control status (the most restrictive under US law, classifying a drug as highly addictive and of no medicinal use).

The most notable reclassification debate in recent times followed the landmark approval of Epidiolex, the first-ever marijuana-derived medicine.

The FDA urged the reclassification of marijuana but the DEA resisted, opting instead to reschedule Epidiolex specifically but nothing more.

“We should be clear that psilocybin is not without risks of harm, which are greater in recreational than medical settings,”says Matthew Johnson from Johns Hopkins, “but relatively speaking, looking at other drugs both legal and illegal, it comes off as being the least harmful in different surveys and across different countries.”

Share this post:
tags: Depression | Health

Facebook is heavily censoring information from independent sources.

To bypass internet censorship, connect with us directly by enabling our notifications (using the red subscription bell in the bottom right corner) or by subscribing to our free daily newsletter.

Get the latest news delivered straight to your inbox for free every day by signing up below.


Subscribe to our mailing list

Whatfinger banner

Follow Neon Nettle